CARDIFF ONCOLOGY, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CARDIFF ONCOLOGY, INC. (CRDF) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-03-02
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $3.06M.
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $3.06M.
- CARDIFF ONCOLOGY, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $3.06M derived: sum of 2 quarters · filed 2023-03-02 | $3.06M 10-K · filed 2023-03-02 | |
| 2021-09-30 | $3.06M 10-Q · filed 2022-11-03 | $3.06M 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 10-K · filed 2022-02-24 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $2.50M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | $2.50M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $2.50M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |